• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Risk factors for severe respiratory syncytial virus lower respiratory tract infection.严重呼吸道合胞病毒下呼吸道感染的危险因素。
Open Microbiol J. 2011;5:144-54. doi: 10.2174/1874285801105010144. Epub 2011 Dec 30.
2
Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.帕利珠单抗预防高危婴儿和幼儿呼吸道合胞病毒(RSV)毛细支气管炎的免疫预防作用:亚组分析的系统评价和额外的经济建模。
Health Technol Assess. 2011 Jan;15(5):iii-iv, 1-124. doi: 10.3310/hta15050.
3
Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.英国婴儿人群使用帕利珠单抗(Synagis)预防呼吸道合胞病毒的成本效果更新分析。
J Med Econ. 2020 Dec;23(12):1640-1652. doi: 10.1080/13696998.2020.1836923. Epub 2020 Oct 27.
4
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.帕利珠单抗是一种人源化呼吸道合胞病毒单克隆抗体,可降低高危婴儿因呼吸道合胞病毒感染而住院的几率。IMpact-RSV研究小组。
Pediatrics. 1998 Sep;102(3 Pt 1):531-7.
5
A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.对帕利珠单抗用于呼吸道合胞病毒免疫预防给药依从性的系统评价。
J Manag Care Pharm. 2010 Jan-Feb;16(1):46-58. doi: 10.18553/jmcp.2010.16.1.46.
6
Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab.接受预防性帕利珠单抗治疗的儿童因呼吸道合胞病毒感染而住院的风险因素。
Eur J Pediatr. 2022 Feb;181(2):539-547. doi: 10.1007/s00431-021-04216-7. Epub 2021 Aug 21.
7
Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.帕利珠单抗预防治疗对早产儿 RSV 相关下呼吸道感染发生率的影响:预防治疗理想目标人群的确定。
Eur J Clin Microbiol Infect Dis. 2017 Sep;36(9):1629-1634. doi: 10.1007/s10096-017-2976-x. Epub 2017 Apr 8.
8
Risk Factors for Hospitalization due to Lower Respiratory Tract Infection in Preterm Infants on Palivizumab Prophylaxis.接受帕利珠单抗预防的早产儿因下呼吸道感染住院的危险因素。
Iran J Pediatr. 2013 Dec;23(6):693-700.
9
Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.帕利珠单抗和呼吸道合胞病毒免疫球蛋白静脉注射剂预防呼吸道合胞病毒感染的修订使用指征。
Pediatrics. 2003 Dec;112(6 Pt 1):1442-6.
10
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.尼塞利珠单抗预防早产儿和足月儿呼吸道合胞病毒下呼吸道感染的疗效,以及对伴有先天性心脏病和慢性肺部疾病的婴儿的药代动力学外推:一项随机对照试验的汇总分析。
Lancet Child Adolesc Health. 2023 Mar;7(3):180-189. doi: 10.1016/S2352-4642(22)00321-2. Epub 2023 Jan 9.

引用本文的文献

1
Factors associated with intubation and heated high-flow nasal cannula use in hospitalized respiratory syncytial virus infected children: A single-center retrospective cohort study.住院呼吸道合胞病毒感染儿童气管插管和使用温热高流量鼻导管相关因素:一项单中心回顾性队列研究
PLoS One. 2025 Aug 7;20(8):e0327541. doi: 10.1371/journal.pone.0327541. eCollection 2025.
2
Age Matters: Key Contributors to Interferon Toxicity in Infants During Influenza Virus Infection.年龄很重要:流感病毒感染期间婴儿干扰素毒性的关键促成因素
Viruses. 2025 Jul 17;17(7):1002. doi: 10.3390/v17071002.
3
Dynamics of Respiratory Syncytial Virus Illness and Serology During Pregnancy and Infancy in the United States and South Africa.美国和南非孕期及婴儿期呼吸道合胞病毒疾病与血清学的动态变化
Open Forum Infect Dis. 2025 Jul 1;12(7):ofaf386. doi: 10.1093/ofid/ofaf386. eCollection 2025 Jul.
4
Pediatric respiratory syncytial virus rehospitalization rate - a retrospective observational study from Switzerland.小儿呼吸道合胞病毒再住院率——一项来自瑞士的回顾性观察研究
BMC Pediatr. 2025 Jul 12;25(1):550. doi: 10.1186/s12887-025-05887-z.
5
Risk Factors for Severe Disease Among Children Hospitalized With Respiratory Syncytial Virus.呼吸道合胞病毒住院儿童重症疾病的危险因素
JAMA Netw Open. 2025 Apr 1;8(4):e254666. doi: 10.1001/jamanetworkopen.2025.4666.
6
Twins with at least one with CHD and their immunisation status in direct comparison-are both twins complying with the German immunisation recommendations?至少有一人患有先天性心脏病的双胞胎及其免疫状况的直接比较——双胞胎都遵循德国免疫建议吗?
Cardiovasc Diagn Ther. 2024 Dec 31;14(6):1108-1121. doi: 10.21037/cdt-24-302. Epub 2024 Dec 9.
7
Trend of pathogens and respiratory co-infections in the province of Messina: from pediatric age to senescence.梅西纳省病原体及呼吸道合并感染的趋势:从儿童期到老年期
J Prev Med Hyg. 2024 Oct 31;65(3):E344-E355. doi: 10.15167/2421-4248/jpmh2024.65.3.3344. eCollection 2024 Sep.
8
Evaluating the Economic and Epidemiological Impact of RSV Hospitalizations in Southern Austria [Southern Austria Respiratory Syncytial Virus INpatient Investigation (ARNI Study)].评估奥地利南部呼吸道合胞病毒住院的经济和流行病学影响[奥地利南部呼吸道合胞病毒住院调查(ARNI 研究)]。
Influenza Other Respir Viruses. 2024 Nov;18(11):e70046. doi: 10.1111/irv.70046.
9
Respiratory Syncytial Virus Infections in Pediatric Intensive Care: Association of Sociodemographic Data and Clinical Outcomes with Viral and Bacterial Co-infections.儿科重症监护中的呼吸道合胞病毒感染:社会人口统计学数据及临床结局与病毒和细菌合并感染的关联
Turk Arch Pediatr. 2024 Sep 2;59(5):494-500. doi: 10.5152/TurkArchPediatr.2024.24149.
10
First real-world data on universal respiratory syncytial virus prophylaxis with Nirsevimab in infants.首次在婴儿中使用 Nirsevimab 进行普遍呼吸道合胞病毒预防的真实世界数据。
J Prev Med Hyg. 2024 Aug 31;65(2):E172-E187. doi: 10.15167/2421-4248/jpmh2024.65.2.3329. eCollection 2024 Jun.

本文引用的文献

1
European risk factors' model to predict hospitalization of premature infants born 33-35 weeks' gestational age with respiratory syncytial virus: validation with Italian data.用于预测孕33 - 35周出生的呼吸道合胞病毒感染早产儿住院情况的欧洲风险因素模型:基于意大利数据的验证
J Matern Fetal Neonatal Med. 2011 Jan;24(1):152-7. doi: 10.3109/14767058.2010.482610. Epub 2010 May 21.
2
Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent?健康早产婴儿中的严重呼吸道合胞病毒感染:我们试图预防什么?
Paediatr Child Health. 1998 Nov;3(6):402-4. doi: 10.1093/pch/3.6.402.
3
Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis.全球儿童因呼吸道合胞病毒导致的急性下呼吸道感染负担:系统评价和荟萃分析。
Lancet. 2010 May 1;375(9725):1545-55. doi: 10.1016/S0140-6736(10)60206-1.
4
Scope and impact of early and late preterm infants admitted to the PICU with respiratory illness.早期和晚期早产儿因呼吸疾病入住 PICU 的范围和影响。
J Pediatr. 2010 Aug;157(2):209-214.e1. doi: 10.1016/j.jpeds.2010.02.006. Epub 2010 Mar 24.
5
Validation of a model to predict hospitalization due to RSV of infants born at 33-35 weeks' gestation.预测 33-35 孕周出生婴儿因 RSV 住院的模型验证。
J Perinat Med. 2010 Jul;38(4):411-7. doi: 10.1515/jpm.2010.074.
6
Population based external validation of a European predictive model for respiratory syncytial virus hospitalization of premature infants born 33 to 35 weeks of gestational age.基于人群的欧洲预测模型对胎龄 33 至 35 周早产儿因呼吸道合胞病毒住院的外部验证。
Pediatr Infect Dis J. 2010 Apr;29(4):374-6. doi: 10.1097/INF.0b013e3181c810da.
7
Impact of palivizumab on RSV hospitalizations for children with hemodynamically significant congenital heart disease.帕利珠单抗对患有血流动力学显著先天性心脏病儿童的呼吸道合胞病毒住院治疗的影响。
Pediatr Cardiol. 2010 Jan;31(1):90-5. doi: 10.1007/s00246-009-9577-0. Epub 2009 Nov 14.
8
High incidence of recurrent wheeze in children with down syndrome with and without previous respiratory syncytial virus lower respiratory tract infection.唐氏综合征患儿在有和无先前呼吸道合胞病毒下呼吸道感染时喘息复发的发生率较高。
Pediatr Infect Dis J. 2010 Jan;29(1):39-42. doi: 10.1097/INF.0b013e3181b34e52.
9
From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections.美国儿科学会:政策声明——关于使用帕利珠单抗预防呼吸道合胞病毒感染的修订建议。
Pediatrics. 2009 Dec;124(6):1694-701. doi: 10.1542/peds.2009-2345. Epub 2009 Sep 7.
10
Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes.患有神经肌肉疾病和免疫缺陷综合征的婴儿的严重呼吸道合胞病毒(RSV)感染
Paediatr Respir Rev. 2009 Sep;10(3):148-53. doi: 10.1016/j.prrv.2009.06.003. Epub 2009 Jul 19.

严重呼吸道合胞病毒下呼吸道感染的危险因素。

Risk factors for severe respiratory syncytial virus lower respiratory tract infection.

作者信息

Sommer Constanze, Resch Bernhard, Simões Eric A F

机构信息

Medical University Graz, Austria.

出版信息

Open Microbiol J. 2011;5:144-54. doi: 10.2174/1874285801105010144. Epub 2011 Dec 30.

DOI:10.2174/1874285801105010144
PMID:22262987
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3258650/
Abstract

RSV infection is a leading cause of lower respiratory tract infection, especially in High-risk infants with a history of prematurity, bronchopulmonary dysplasia (BPD), congenital heart disease (CHD), neuromusculair impairment, immunodeficiency, and Down syndrome. Host related risk factors that have been identified to be associated with severe RSV related lower respiratory tract infection include young age below 6 months at the beginning of RSV season, multiple birth, male sex, low socioeconomic status and parental education, crowded living conditions, young siblings, maternal smoking and indoor smoke pollution, malnutrition/small for gestational age, family history of atopy or asthma, low cord serum RSV antibody titers, and living at altitude.Risk factors increasing the risk of acquisition of RSV have been identified to be birth before and/or during RSV season, day care attendance, presence of older siblings in school or day-care, and lack of breast feeding. Some of these risk factors are discussed controversially and some of them are found continuously throughout the literature.Given the high cost of RSV prophylaxis, especially for the large population of late preterm infants, algorithms and risk score systems have been published that could identify high-risk infants for treatment with palivizumab out of this gestational age group. Several models reported on an average sensitivity and specificity of 70 percent and, thus, are helpful to identify infants at high risk for severe RSV infection and need for prophylaxis with palivizumab.

摘要

呼吸道合胞病毒(RSV)感染是下呼吸道感染的主要原因,尤其在具有早产、支气管肺发育不良(BPD)、先天性心脏病(CHD)、神经肌肉损伤、免疫缺陷和唐氏综合征病史的高危婴儿中。已确定与严重RSV相关下呼吸道感染相关的宿主相关危险因素包括RSV季节开始时6个月以下的幼儿、多胞胎、男性、社会经济地位低和父母教育程度低、居住条件拥挤、年幼的兄弟姐妹、母亲吸烟和室内烟雾污染、营养不良/小于胎龄、特应性或哮喘家族史、脐带血清RSV抗体滴度低以及居住在高海拔地区。已确定增加RSV感染风险的危险因素包括在RSV季节之前和/或期间出生、日托、学龄期或日托机构中有年长的兄弟姐妹以及缺乏母乳喂养。其中一些危险因素存在争议,并且在整个文献中不断被发现。鉴于RSV预防成本高昂,尤其是对于大量晚期早产儿群体,已发布了算法和风险评分系统,可从该孕周组中识别出需要使用帕利珠单抗治疗的高危婴儿。有几个模型报告的平均敏感性和特异性为70%,因此有助于识别严重RSV感染高危婴儿以及是否需要使用帕利珠单抗进行预防。